Skip to main content
N4 PHARMA PLC logo

N4 PHARMA PLC — Investor Relations & Filings

Ticker · N4P ISIN · GB00BYW8QM32 LEI · 213800I841D2RKMFK955 IL Professional, scientific and technical activities
Open in API
Filings indexed 840 across all filing types
Latest filing 2020-09-30 Regulatory Filings
Country GB United Kingdom
Listing IL N4P

About N4 PHARMA PLC

https://n4pharma.com/

N4 Pharma PLC is a specialist pharmaceutical company focused on the development of Nuvec®, its proprietary silica nanoparticle delivery system. This platform technology is designed to enhance the cellular delivery and potency of nucleic acid-based treatments, such as vaccines and cancer therapies. The company's primary focus is on applying Nuvec® to enable advanced therapies for oncology and infectious diseases. N4 Pharma's business model involves developing and out-licensing its technology to pharmaceutical and biotechnology partners to improve the performance of new and existing drugs.

Recent filings

Filing Released Lang Actions
Total Voting Rights
Regulatory Filings Classification · 1% confidence The document is very short (3232 characters) and its primary purpose is to announce the 'Total Voting Rights' as of a specific date (30 September 2020). It explicitly states the total number of shares and voting rights, which is information shareholders use for regulatory notification calculations under the FCA's Disclosure Guidance and Transparency Rules. This type of announcement, often released via RNS (as indicated by the RNS Number and footer), relates to the company's capital structure and shareholder notification requirements. While it touches upon share capital, it is not a formal share issue (SHA) or a transaction in own shares (POS). It is a mandatory regulatory disclosure regarding the denominator for ownership tracking. Given the options, this specific type of capital/shareholder rights announcement that is not a dividend or major shareholding change fits best under the general 'Regulatory Filings' (RNS) category, as it is a routine regulatory update provided through the RNS system, or potentially related to voting rights (DVA), but DVA is specifically for *results* of votes. Since it's a routine regulatory update about the share base used for voting/disclosure, RNS is the most appropriate general regulatory fallback.
2020-09-30 English
Appointment of Chief Executive Officer
Board/Management Information Classification · 1% confidence The document is a formal announcement disseminated via RNS (Regulatory News Service) of the London Stock Exchange, indicated by the 'RNS Number' header and the concluding boilerplate text referencing RNS and the FCA. The core content announces the 'Appointment of Chief Executive Officer' (Huw Jones PhD). This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition of Board/Management Information (MANG). Although it is an RNS filing, the specific content is highly targeted, making MANG a more precise classification than the general RNS fallback.
2020-09-24 English
Verona Pharma Initiates Phase 3 Clinical Trials with Nebulized Ensifentrine for the Maintenance Treatment of COPD
Earnings Release Classification · 1% confidence The document is a press release issued by Verona Pharma plc, announcing the initiation of its ENHANCE Phase 3 clinical trials for nebulized ensifentrine in COPD patients. It details the study design, endpoints, and provides background information on the drug and the disease. This type of announcement, focusing on clinical trial progress and strategic operational updates, is characteristic of an Earnings Release (ER) or a general corporate update. Since it is a press release announcing significant operational news (Phase 3 trial initiation) rather than a formal, comprehensive financial report (like 10-K or IR), and it is not a transcript (CT), proxy material (PSI), or a specific transaction notice (DIV, POS, DIRS), the most fitting category is Earnings Release (ER), as these often accompany or precede quarterly financial reporting periods, or serve as major operational news announcements. Given the context of a clinical-stage biopharma company, major trial updates are often released as ERs or RNS. Since it contains substantial detail about the program and CEO commentary, ER is a strong fit, though RNS is a possibility if it were purely regulatory. Given the structure and content, ER is preferred over the general RNS fallback. Q3 2020
2020-09-23 English
Intended Delisting and Cancellation of Ordinary Shares from Trading on AIM
Delisting Announcement Classification · 1% confidence The document explicitly announces the 'intention to cancel the admission to trading of the Company’s ordinary shares (“Ordinary Shares”) on AIM (the “AIM Delisting”).' It provides specific dates for the last day of trading and the effective delisting time. This action directly relates to the company's stock exchange listing status and is a formal notice of removal from a trading venue (AIM). This aligns perfectly with the definition of a Delisting Announcement (DLST). Although it mentions shareholder voting rules (AIM Rules), the core purpose is the announcement of the delisting itself, not the results of a vote (DVA) or general governance rules (CGR).
2020-09-21 English
Verona Pharma to Ring the Nasdaq Closing Bell to celebrate $200 million financing
Capital/Financing Update Classification · 1% confidence The document is a press release announcing that the CEO of Verona Pharma will ring the Nasdaq closing bell to celebrate a recent $200 million financing. It discusses clinical trial progress (Phase 3 ENHANCE), product details (Ensifentrine), and future plans. This type of announcement, focusing on corporate events, financing milestones, and general business updates rather than detailed periodic financial results (like 10-K or IR) or a formal transcript, fits best under a general corporate announcement category. Since it is a press release about corporate activity and financing milestones, it is most closely related to Capital/Financing Update (CAP) or a general Regulatory Filing (RNS). Given the primary focus on celebrating a major financing event and providing a business update, 'CAP' is a strong candidate, but 'RNS' (Regulatory Filings/General Announcement) is often used for these types of press releases that don't fit the specific financial report codes. However, the text explicitly mentions the $200 million equity financing and the CEO's remarks about being 'well capitalized to support our operations and Phase 3 clinical program into 2023.' This strong emphasis on financing makes 'CAP' (Capital/Financing Update) the most specific fit among the options, as it is an announcement related to capital structure changes/fundraising success. It is not a full report (10-K, IR) nor a transcript (CT).
2020-09-17 English
Interim Results
Interim / Quarterly Report Classification · 1% confidence The document is titled 'unaudited interim results for the six months ended 30 June 2020' and contains comprehensive financial statements, including the 'Condensed Consolidated Interim Statement of Comprehensive Income' and 'Condensed Consolidated Interim Statement of Financial Position'. It provides detailed financial data, management commentary, and operational updates for a period shorter than a full fiscal year. It meets the criteria for an Interim/Quarterly Report (IR) rather than a mere announcement, as it includes the actual financial statements. H1 2020
2020-09-17 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.